Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.

Share Price

Set up a new alert »
Bid Price High Price
Ask Price Low Price
Open Price Spread
Prev Close Volume

Dechra Pharmaceuticals Historic Prices

Date Open High Low Close Volume
Oct 18, 2019 2,750.00 2,750.00 2,616.00 2,626.00 335,044
Oct 17, 2019 2,656.00 2,694.00 2,612.00 2,676.00 282,346
Oct 16, 2019 2,618.68 2,650.00 2,606.00 2,626.00 438,638
Oct 15, 2019 2,634.00 2,660.00 2,594.00 2,618.00 655,955
Oct 14, 2019 2,566.00 2,630.00 2,554.00 2,630.00 518,469
More Dechra Pharmaceuticals Historic Prices >
Intraday
Historic - 1 year
Advanced Dechra Pharmaceuticals Charts >

Dechra Pharmaceuticals Information

Name Dechra Pharmaceuticals Epic DPH
ISIN GB0009633180 Currency GBX
Type Equity Trading Segment STMM
Record Status Active Trading Status Closed
Industry Health Care Sector Pharmaceuticals
EMS 750 Prev Close 2,626.00
Shares in Issue (m) 102.81 Market Cap (£m) 2,699.76
PE Ratio 87.10 Div per Share (p) 31.60
Div Yield 1.20 Div Cover 0.95
EPS 30.15 EPS Growth (%) -19.04
PEG -4.57 DPS Growth (%) 23.92
ROCE 2.99 Net Gearing 43.79
Quick Ratio 1.59 Current Ratio 2.47

Dechra Pharmaceuticals Broker Views

Date Broker Recomm. Price Old Target New Target Notes
04 Sep JP Morgan Cazenove Overweight 2,626.00 3,000.00 3,500.00 Reiterates
25 Mar Jefferies International Buy 2,626.00 2,466.00 2,805.00 Reiterates
25 Mar JP Morgan Cazenove Overweight 2,626.00 - 3,000.00 Initiates/Starts
11 Mar HSBC Buy 2,626.00 2,770.00 2,700.00 Reiterates
12 Feb HSBC Buy 2,626.00 - 2,770.00 Initiates/Starts
More Dechra Pharmaceuticals Broker Views >

Dechra Pharmaceuticals Director Deals

Date Director Type Volume / Price Trade Value
23 Sep 2019 Ian Page Exercise 73,260 @ 0.00p £0.00
23 Sep 2019 Ian Page Sale Post-Exercise 34,536 @ 2,789.37p £963,338.38
18 Sep 2019 Ian Page Sell 200,000 @ 2,916.95p £5,833,900.00
18 Sep 2019 Tony Rice Sell 20,000 @ 2,909.97p £581,993.60
19 Dec 2018 Tony Griffin Sell 5,000 @ 2,115.37p £105,768.50
More Dechra Pharmaceuticals Director Deals >

Dechra Pharmaceuticals News